Antisense therapies for treating cancer

US11643656B2 · kind B2 · utility

Assignees

• The Regents of the University of California · US
• The United States Government represented by the Department of Veterans Affairs · US

Inventors

• Robert Bell · Oakland, US
• Joseph F. Costello · Oakland, US
• Daniel A. Lim · San Francisco, US
• Andrew Mancini · Oakland, US

Key dates

• Filing date: May 24, 2018
• Grant date: May 9, 2023
• Expiry date: May 24, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/3513
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides methods for cancers associated with a TERT promoter mutation in a subject. In some embodiments, the methods comprise administering to the subject a therapeutically effective amount of an agent that specifically reduces or inhibits GA binding protein transcription factor beta subunit 1 long isoform (GABPBIL) expression or function.